Hong Kong, 01 September 2026 — China Biotech Services Holdings Limited (CH BIOTECH SER) has released its Monthly Return for the period ended 31 August 2026, indicating a steady capital structure alongside sizeable outstanding convertible instruments. Key highlights follow:

Authorised and Issued Capital • Authorised share capital remained unchanged at 2.00 billion ordinary shares with par value of HKD 0.10, representing HKD 200.00 million in registered capital. • Issued shares stood at 975.73 million, with no change during August. The company held no treasury shares. • The issuer confirmed compliance with the minimum 25% public-float requirement under Hong Kong listing rules.

Convertible Bond Profile and Potential Dilution • 2024 Convertible Bonds: USD 6.00 million in principal, convertible at HKD 1.11 per share, allowing up to 42.43 million new shares on full conversion. Maturity is 27 December 2026. • 2026 Convertible Bonds: USD 35.00 million in principal, convertible at HKD 0.66 per share, allowing up to 412.58 million new shares on full conversion. Maturity is 20 February 2030. • Combined, the two tranches could add up to 455.01 million new shares, equivalent to roughly 46.6% of the current issued share base, if fully converted.

Other Equity Instruments • The company reported no outstanding share option schemes, warrants, or other share-issuance arrangements during the month. • No share repurchases, cancellations, or treasury share movements were recorded.

Governance and Compliance • The board confirmed that all issued securities comply with the Hong Kong Stock Exchange listing rules and that requisite filings and approvals are in place.

Outlook With no share issuance in August, China Biotech Services maintains its issued share capital at 975.73 million shares. However, the sizeable potential conversion of USD 41.00 million in outstanding bonds represents a meaningful source of future dilution, contingent on market conditions and bondholder decisions ahead of the 2026 and 2030 maturities.